<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Since cellular uptake of <z:chebi fb="77" ids="46793">PEG</z:chebi> [<z:chebi fb="0" ids="46793">poly(ethylene glycol)</z:chebi>]-liposomal L-OHP (<z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>) induces bioactive changes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (<z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>), we have investigated its apoptotic effect and anticancer mechanism </plain></SENT>
<SENT sid="1" pm="."><plain>Human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> SW480 cells were treated with <z:chebi fb="77" ids="46793">PEG</z:chebi>-liposomal L-OHP and a caspase-8 inhibitor [Z-IETD-FMK (benzyloxycarbonyl<z:chebi fb="84" ids="32607">-Ile</z:chebi>-Glu-Thr-dl-Asp-fluoromethylketone)] </plain></SENT>
<SENT sid="2" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was measured by FCM (flow cytometry) and TUNEL (terminal deoxynucleotidyl transferase-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi> nick-end labelling) assay </plain></SENT>
<SENT sid="3" pm="."><plain>Expression of Fas/FasL and <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> was detected using FCM and an immunofluorescence assay </plain></SENT>
<SENT sid="4" pm="."><plain>Expression of caspase-8, Bid, caspase-9, caspase-7 and activated caspase-3 (P17) was examined by Western blot analyses </plain></SENT>
<SENT sid="5" pm="."><plain>The results indicated that <z:chebi fb="77" ids="46793">PEG</z:chebi>-liposomal L-OHP (28 μg/ml L-OHP) induced marked <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in SW480 cells compared with 28 μg/ml free L-OHP </plain></SENT>
<SENT sid="6" pm="."><plain>The expression levels of Fas, FasL, <z:chebi fb="1" ids="18070">cytochrome c</z:chebi>, caspase-9, caspase-7 and activated caspase-3 proteins were up-regulated, with a corresponding increase in <z:mpath ids='MPATH_3'>apoptosis</z:mpath>; however, expression of caspase-8 and Bid were down-regulated as <z:mpath ids='MPATH_3'>apoptosis</z:mpath> increased </plain></SENT>
<SENT sid="7" pm="."><plain>When cells were treated with Z-IETD-FMK, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was inhibited, but there was little impact on the expression of Fas, FasL, <z:chebi fb="1" ids="18070">cytochrome c</z:chebi>, Bid, caspase-9, caspase-7 and activated caspase-3 </plain></SENT>
<SENT sid="8" pm="."><plain>These findings indicate that <z:chebi fb="77" ids="46793">PEG</z:chebi>-liposomal L-OHP enhances the anticancer potency of the chemotherapeutic agent; moreover, Fas/FasL and caspase-8 signalling pathways play a key role in mediating <z:chebi fb="77" ids="46793">PEG</z:chebi>-liposomal L-OHP-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
</text></document>